Skip to main content
Clinical Trials/KCT0008194
KCT0008194Recruiting未知

ong-term effect of safinamide on motor and non-motor symptoms of Parkinson’s disease

Jeonbuk National University Hospital0 sites50 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational Study

Eligibility Criteria

Ages
o Limit to o Limit (—)
Sex
All

Inclusion Criteria

  • 1. Diagnosis of Parkinson’s disease according to the United Kingdom Parkinson’s Disease Society Brain Bank criteria.
  • 2. Subjects for whom the decision to initiate Safinamide has been made, according to the judgment of the investigator, who is the neurologist specialized in movement disorder. (The judgement is based on existing evidence and reports on symptoms that have previously reported to be improved by safinamide, which includes the presence of motor fluctuation.)
  • 3. Stable dopaminergic treatment in the last 4 weeks. (Patients already taking other iMAO-B, such as rasagiline or selegiline, were switched to safinamide 50 mg after a 2-week wash-out period)
  • 4. To wish to voluntarily participate and to sign a consent form.

Exclusion Criteria

  • 1. other disabling concomitant neurological disease (stroke, severe head trauma, neurodegenerative disease, etc.) or other severe and disabling concomitant non-neurological disease (oncological, autoimmune, etc.)
  • 2. incapacity to complete the questionnaires adequately
  • 3. Contraindication to be treated with safinamide according to product data.

Investigators

Similar Trials